ACET

Adicet Bio, Inc. ACET

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$1.15M

Quarter to Jun 30

Net income

$-21.36M

Quarter to Jun 30

Free cash flow

$-20.02M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$52.79M total
RA CAPITAL MANAGEMENT, L.P.
$8.06M-21.1%
ORBIMED ADVISORS LLC
$7.30M-17.8%
FRANKLIN RESOURCES INC
$5.41M0.0%
CITADEL ADVISORS LLC
$3.74M+13.3%
VANGUARD CAPITAL MANAGEMENT LLC
$2.97M+2.0%
ADAGE CAPITAL PARTNERS GP, L.L.C.
$2.37M0.0%
RENAISSANCE TECHNOLOGIES LLC
$2.30M+14.3%
Stonepine Capital Management, LLC
$2.12M+10.6%
Alyeska Investment Group, L.P.
$1.76M0.0%
Schonfeld Strategic Advisors LLC
$1.69MNew
Carlyle Group Inc.
$1.59M0.0%
NEXTBio Capital Management LP
$1.36M0.0%
ACADIAN ASSET MANAGEMENT LLC
$1.08M+5.7%
TWO SIGMA INVESTMENTS, LP
$836.7K+124.7%
GEODE CAPITAL MANAGEMENT, LLC
$826.7K-5.4%
DAFNA Capital Management LLC
$810.5K0.0%
BRIDGEWAY CAPITAL MANAGEMENT, LLC
$742.7KNew
MARSHALL WACE, LLP
$686.8KNew
Trexquant Investment LP
$673.9K+78.6%
JANE STREET GROUP, LLC
$609.6K+90.3%
Burkehill Global Management, LP
$540.0K0.0%
BlackRock, Inc.
$536.8K+69.8%
REGENERON PHARMACEUTICALS, INC.
$522.8K0.0%
Rangeley Capital, LLC
$439.7K-9.1%
VANGUARD FIDUCIARY TRUST CO
$437.8K+0.7%
See all 56 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/ACET

Earnings Per Share

13fpro.ai/company/ACET

Loading ratio trend…

ACET insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Adicet Bio, Inc. (ACET): stock profile, AI score and financials

Adicet Bio, Inc. (ACET) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. ACET is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Adicet Bio, Inc. reports quarterly revenue of $1.1M, net income of $-21.4M, free cash flow of $-20.0M. Top institutional holders of ACET by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., ORBIMED ADVISORS, FRANKLIN RESOURCES, based on the most recent SEC filings. ACET trades on the Nasdaq exchange and files with the SEC under CIK 1720580. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ACET daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Adicet Bio, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1720580 →